Connection

Robert Grubb to Mass Screening

This is a "connection" page, showing publications Robert Grubb has written about Mass Screening.
Connection Strength

0.764
  1. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008 Dec; 102(11):1524-30.
    View in: PubMed
    Score: 0.207
  2. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019 05; 123(5):854-860.
    View in: PubMed
    Score: 0.103
  3. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012 Jan 18; 104(2):125-32.
    View in: PubMed
    Score: 0.064
  4. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011 Feb 01; 29(4):355-61.
    View in: PubMed
    Score: 0.059
  5. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26; 360(13):1310-9.
    View in: PubMed
    Score: 0.053
  6. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control. 2008 Dec; 19(10):1267-76.
    View in: PubMed
    Score: 0.050
  7. The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nat Clin Pract Urol. 2007 Nov; 4(11):605-14.
    View in: PubMed
    Score: 0.048
  8. Results of compliance with prostate cancer screening guidelines. J Urol. 2005 Aug; 174(2):668-72; discussion 672.
    View in: PubMed
    Score: 0.041
  9. Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. J Urol. 2005 Apr; 173(4):1116-20.
    View in: PubMed
    Score: 0.040
  10. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst. 2005 Mar 16; 97(6):433-8.
    View in: PubMed
    Score: 0.040
  11. Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. Cancer Epidemiol Biomarkers Prev. 2013 Dec; 22(12):2241-9.
    View in: PubMed
    Score: 0.018
  12. Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol. 2012 Dec; 36(6):e401-6.
    View in: PubMed
    Score: 0.017
  13. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):748-51.
    View in: PubMed
    Score: 0.013
  14. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int. 2007 Apr; 99(4):775-9.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.